Tearsheet
Investment Highlights Market Valuation Price Chart Return vs. Risk About LENZ Interactive Breakdown Better Bets vs. LENZ Latest Trefis Analyses Trade Ideas Recent Active Movers More From Trefis Peer Financials Peer Growth & Margins Peer Valuation Peer Returns Peer Analyses FDIC Bank Data Financials Segment Financials Price Behavior Short Interest Earnings Returns History SEC Filings Insider Activity Industry Resource Links External Quote Links

LENZ Therapeutics (LENZ)

Market Price (10/31/2025): $30.64 | Market Cap: $843.4 Mil
Sector: Health Care | Industry: Biotechnology

LENZ Therapeutics (LENZ)

Market Price (10/31/2025): $30.64
Market Cap: $843.4 Mil
Sector: Health Care
Industry: Biotechnology

Investment Highlights Why It Matters Which of these 2 stories sounds closer for this stock?

1. Generates cash flow

The stock generated 4% or more of the share price (called cash flow yield), and shows moderate 10-15% or more growth.

2. Riding a trend

Think Tesla during the pandemic of 2020 when EVs were riding a cultural high, or Nvidia in the current AI boom, or even Figma. These companies don’t have enough yield, or, enough growth, or both - however - they are riding a trend. They have momentum. These can be more volatile - they don’t have the floor of strong cash flow

0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -23%		  Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
1   Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -59 Mil
2   Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -10%
3   Significant short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 21%
0 Cash is significant % of market cap
Net D/ENet Debt/Equity. Debt net of cash. Negative indicates net cash. Equity is taken as the Market Capitalization is -23%
1 Very low revenue
Rev LTMTotal Revenue or Sales, Last Twelve Months is 0
2 Not profitable at operating income level
Op Inc LTMOperating Income, Last Twelve Months is -59 Mil
3 Yield minus risk free rate is negative
ERPEquity Risk Premium (ERP) = Total Yield - Risk Free Rate, Reflects the premium above risk free assets offered by the investment. is -10%
4 Significant short interest
Short Interest % of Basic SharesShort Interest % of Basic Shares = (Short Interest Quantity) / (Basic Shares Outstanding). A high fraction of short interest can indicate potential risk of a short squeeze. is 21%

Market Valuation & Key Metrics

null

LENZ Stock

   
   
   
   
   
   
   
Factor Drivers of Stock Movement
The 5.5% change in LENZ stock from 5/1/2025 to 10/30/2025 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

501202510302025Change
Stock Price ($)28.8830.465.47%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)0.000.00�
P/S Multiple∞∞�
Shares Outstanding (Mil)25.5327.53-7.80%
Cumulative Contribution�

LTM = Last Twelve Months as of date shown
The 10.2% change in LENZ stock from 10/30/2024 to 10/30/2025 was primarily driven by a 0.0% change in the company's Total Revenues ($ Mil).

1030202410302025Change
Stock Price ($)27.6430.4610.20%
Change Contribution ByLTMLTM
Total Revenues ($ Mil)�0.00�
P/S Multiple�∞�
Shares Outstanding (Mil)25.5327.53-7.80%
Cumulative Contribution�

LTM = Last Twelve Months as of date shown
null

null

Return vs. Risk

Price Returns Compared

 202020212022202320242025Total [1]
Returns
LENZ Return---73%-21%1002%6%157%
Peers Return-15%-9%-6%-3%-3%-16%-43%
S&P 500 Return16%27%-19%24%23%16%110%

Monthly Win Rates [3]
LENZ Win Rate-17%42%42%67%78% 
Peers Win Rate18%15%23%31%22%51% 
S&P 500 Win Rate58%75%42%67%75%67% 

Max Drawdowns [4]
LENZ Max Drawdown---83%-44%-0%-37% 
Peers Max Drawdown-20%-13%-14%-15%-30%-27% 
S&P 500 Max Drawdown-31%-1%-25%-1%-2%-15% 

[1] Cumulative total returns since the beginning of 2020
[2] Peers: VRTX, APM, BBOT, GDTC, HIND.
[3] Win Rate = % of calendar months in which monthly returns were positive
[4] Max drawdown represents maximum peak-to-trough decline within a year
[5] 2025 data is for the year up to 10/30/2025 (YTD)

How Low Can It Go

Unique KeyEventLENZS&P 500
2022 Inflation Shock2022 Inflation Shock  
2022 Inflation Shock% Loss% Loss-94.0%-25.4%
2022 Inflation Shock% Gain to Breakeven% Gain to Breakeven1561.1%34.1%
2022 Inflation ShockTime to BreakevenTime to Breakeven670 days464 days

Compare to VRTX, APM, BBOT, GDTC, HIND


In The Past

LENZ Therapeutics's stock fell -94.0% during the 2022 Inflation Shock from a high on 6/30/2021. A -94.0% loss requires a 1561.1% gain to breakeven.

Preserve Wealth

Limiting losses and compounding gains is essential to preserving wealth over time.

Asset Allocation

Actively managed asset allocation strategies protect wealth. Learn more.

About LENZ Therapeutics (LENZ)

Better Bets than LENZ Therapeutics (LENZ)

 LENZBetter Performance than LENZ
MetricValueIndustry (Biotechnology)
Total Yield-5.7%ABBV (3.7%), AMGN (7.4%), GILD (7.0%), VRTX (3.4%), REGN (7.2%)
 LENZBetter Performance than LENZ
MetricValueAll Other Sectors
Total Yield-5.7%NVDA (1.8%), AAPL (2.8%), MSFT (3.3%), GOOGL (3.9%), AMZN (3.0%)
 Best Bets In Health Care Sector
 LENZRPRX HALO CPRX BMY LNTH PBH BIIB PFE EW ILMN
What You Pay           
P/E-17.615.314.112.315.414.014.013.612.811.812.4
P/EBIT-14.18.111.010.59.39.69.010.110.329.210.3
What You Get           
Rev Chg Q�7.7%40.8%19.4%2.8%-4.1%-6.6%2.8%10.3%11.9%-4.8%
Rev Chg LTM�3.0%35.0%28.5%1.3%5.7%0.6%4.8%13.5%9.1%-3.3%
Rev Chg 3Y Avg�0.8%35.5%49.9%1.0%34.3%0.8%-0.9%-12.4%3.0%-3.0%
FCF/Rev 3Y Avg�113.4%43.4%38.9%29.0%26.1%21.6%17.0%13.8%11.9%9.0%

[1] Choosing top 10 best bets from each sector quarterly is an alpha producing strategy vs sector benchmark
[2] Historical annualized return of 11%, alpha of 1.9%, and sharpe of 0.52

Latest Trefis Analyses

Trade Ideas

Select past ideas related to LENZ. For more, see Trefis Trade Ideas.

Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		5.9%5.9%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		16.1%16.1%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		2.6%2.6%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		14.2%14.2%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		15.2%15.2%-8.0%
Unique KeyDateTickerCompanyCategoryTrade Strategy6M Fwd Rtn12M Fwd Rtn12M Max DD
ADMA_9302025_Dip_Buyer_ValueBuy09302025ADMAADMA BiologicsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		5.9%5.9%-4.6%
REGN_9302025_Dip_Buyer_ValueBuy09302025REGNRegeneron PharmaceuticalsDip BuyDB | P/E OPMDip Buy with Low PE and High Margin
Buying dips for companies with tame PE and meaningfully high operating margin		16.1%16.1%-0.8%
HAE_9262025_Dip_Buyer_High_FCF_Yield_ExInd_DE_RevG09262025HAEHaemoneticsDip BuyDB | FCF Yield | Low D/EDip Buy with High Free Cash Flow Yield
Buying dips for companies with significant free cash flow yield (FCF / Market Cap) and reasonable debt / market cap		2.6%2.6%-0.1%
WAT_9192025_Monopoly_xInd_xCD_Getting_Cheaper09192025WATWatersMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		14.2%14.2%-4.3%
ISRG_9052025_Monopoly_xInd_xCD_Getting_Cheaper09052025ISRGIntuitive SurgicalMonopolyMY | Getting CheaperMonopoly-Like with P/S Decline
Large cap with monopoly-like margins or cash flow generation and getting cheaper based on P/S multiple		15.2%15.2%-8.0%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1INBXInhibrx Biosciences176.8%409.8%
2PUMPProPetro71.2%16.2%
3RNAAvidity Biosciences43.5%139.6%
4DYNDyne Therapeutics42.8%-0.0%
5GCIGannett39.3%3.8%
6FORMFormFactor38.3%34.7%
7MBXMBX Biosciences35.1%18.2%
8BBNXBeta Bionics33.8% 
9GHGuardant Health33.3%202.5%
10LUMNLumen Technologies32.7%94.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-75.2%5106.3%
2LRNStride-56.1%-35.8%
3NTLAIntellia Therapeutics-52.6%5.2%
4FMCFMC-48.7%-66.6%
5FIFiserv-47.4%-68.3%
6VRNSVaronis Systems-43.8%-21.2%
7THRYThryv-33.4%-44.8%
8NFENew Fortress Energy-30.5%-91.9%
9AKBAAkebia Therapeutics-29.5%10.5%
10UAMYUnited States Antimony-28.9%371.2%

1 Month Top Gainers

#TickerCompany1M RtnYTD Rtn
1PRAXPraxis Precision Medicines279.1%161.2%
2INBXInhibrx Biosciences131.0%409.8%
3PUMPProPetro99.6%16.2%
4DYNDyne Therapeutics88.4%-0.0%
5VICRVicor85.4%89.2%
6CELCCelcuity74.6%503.2%
7GLUEMonte Rosa Therapeutics73.5%87.5%
8NVTSNavitas Semiconductor72.1%251.8%
9LUMNLumen Technologies70.3%94.7%
10BALYBallys63.4%4.1%

1 Month Top Losers

#TickerCompany1M RtnYTD Rtn
1PMIPicard Medical-62.9%5106.3%
2LRNStride-53.8%-35.8%
3FMCFMC-51.0%-66.6%
4FIFiserv-48.3%-68.3%
5NFENew Fortress Energy-43.6%-91.9%
6VGVenture Global-41.7% 
7OGNOrganon-40.2%-55.0%
8VRNSVaronis Systems-39.5%-21.2%
9ITGRInteger-38.5%-52.2%
10LENZLENZ Therapeutics-37.9%5.5%

Recent Active Movers

1 Week Top Gainers

#TickerCompany1W RtnYTD Rtn
1INBXInhibrx Biosciences176.8%409.8%
2PUMPProPetro71.2%16.2%
3RNAAvidity Biosciences43.5%139.6%
4DYNDyne Therapeutics42.8%-0.0%
5GCIGannett39.3%3.8%
6FORMFormFactor38.3%34.7%
7MBXMBX Biosciences35.1%18.2%
8BBNXBeta Bionics33.8% 
9GHGuardant Health33.3%202.5%
10LUMNLumen Technologies32.7%94.7%

1 Week Top Losers

#TickerCompany1W RtnYTD Rtn
1PMIPicard Medical-75.2%5106.3%
2LRNStride-56.1%-35.8%
3NTLAIntellia Therapeutics-52.6%5.2%
4FMCFMC-48.7%-66.6%
5FIFiserv-47.4%-68.3%
6VRNSVaronis Systems-43.8%-21.2%
7THRYThryv-33.4%-44.8%
8NFENew Fortress Energy-30.5%-91.9%
9AKBAAkebia Therapeutics-29.5%10.5%
10UAMYUnited States Antimony-28.9%371.2%

More From Trefis

Research & Analysis

Invest in Strategies

Wealth Management

Peer Comparisons for LENZ Therapeutics

Financials

LENZVRTXAPMBBOTGDTCHINDMedian
NameLENZ The.Vertex P.Aptorum BridgeBi.CytoMed .Vyome  
Mkt Price30.46419.891.4712.002.155.588.79
Mkt Cap0.8107.8----54.3
Rev LTM011,419-0--0
Op Inc LTM-59-199--93---93
FCF LTM-523,500--60---52
FCF 3Y Avg-1,984----1,984
CFO LTM-523,846--60---52
CFO 3Y Avg-2,324----2,324

Growth & Margins

LENZVRTXAPMBBOTGDTCHINDMedian
NameLENZ The.Vertex P.Aptorum BridgeBi.CytoMed .Vyome  
Rev Chg LTM-10.5%----10.5%
Rev Chg 3Y Avg-11.0%----11.0%
Rev Chg Q-12.1%----12.1%
QoQ Delta Rev Chg LTM-2.9%----2.9%
Op Mgn LTM--1.7%-----1.7%
Op Mgn 3Y Avg-26.5%----26.5%
QoQ Delta Op Mgn LTM-2.0%----2.0%
CFO/Rev LTM-33.7%----33.7%
CFO/Rev 3Y Avg-22.5%----22.5%
FCF/Rev LTM-30.6%----30.6%
FCF/Rev 3Y Avg-19.2%----19.2%

Valuation

LENZVRTXAPMBBOTGDTCHINDMedian
NameLENZ The.Vertex P.Aptorum BridgeBi.CytoMed .Vyome  
Mkt Cap0.8107.8----54.3
P/S-9.4----9.4
P/EBIT-14.124.5----5.2
P/E-17.629.6----6.0
P/CFO-16.328.0----5.9
Total Yield-5.7%3.4%-----1.2%
Dividend Yield0.0%0.0%----0.0%
FCF Yield 3Y Avg-2.1%----2.1%
D/E0.00.0----0.0
Net D/E-0.2-0.0-----0.1

Returns

LENZVRTXAPMBBOTGDTCHINDMedian
NameLENZ The.Vertex P.Aptorum BridgeBi.CytoMed .Vyome  
1M Rtn-34.6%7.2%-27.2%3.6%8.0%7.7%5.4%
3M Rtn2.3%-8.1%-5.2%-14.4%--1.4%
6M Rtn5.5%-15.8%59.8%--6.5%--0.5%
12M Rtn10.2%-11.6%5.0%--3.4%-0.8%
3Y Rtn767.8%34.6%-76.8%---34.6%
1M Excs Rtn-39.6%2.2%-34.2%-1.9%5.3%-0.2%-1.1%
3M Excs Rtn-7.7%-18.5%-2.1%-8.1%--4.9%
6M Excs Rtn-16.3%-37.6%38.0%--28.3%--22.3%
12M Excs Rtn-10.3%-29.0%-17.8%--33.2%--23.4%
3Y Excs Rtn688.6%-41.0%-151.9%----41.0%

Financials

$ Mil | FY: 12/312025Q12024Q42024Q32024Q22024Q12023Q42023Q32023Q22023Q12022Q4
Period End3/31/202512/31/20249/30/20246/30/20243/31/202412/31/20239/30/20236/30/20233/31/202312/31/2022
Filing Date5/7/20253/19/202511/6/20248/14/20245/8/20243/19/20252/13/20248/14/20245/8/20242/13/2024
Key Financials Quarterly          
Total Revenue0000000000
Ebitda-17-15-13-14-16-25-20-15-13-9
Operating Income-17-15-13-14-16-25-20-15-13-9
Net Income-15-13-10-10-17-24-19-15-13-9
EPS-0.53-0.46-0.38-0.40-3.53-0.93-0.74-0.58-0.50-0.37
Key Financials TTM          
Total Revenue TTM0000000---
Ebitda TTM-59-59-68-75-76-72-57---
Operating Income TTM-59-59-68-75-76-72-57---
Net Income TTM-48-50-61-69-74-70-56---
Growth Rates Quarterly          
Total Revenue Growth----------
EBITDA Growth-5.0%39.2%34.9%4.2%-27.5%-173.8%----
Operating Income Growth-5.2%39.1%34.8%4.1%-27.5%-173.8%----
Net Income Growth12.2%46.6%45.9%30.4%-31.4%-151.3%----
Margins Quarterly          
EBITDA Margin----------
Operating Income Margin----------
Net Income Margin----------
Cash & Debt          
Total Cash1942092171962136688--44
Total Debt1122100000
Net Debt / (Cash)-193-208-216-194-213-65-88---44
Cash Flows Quarterly          
FCF from Operations-16-9-11-16-24-21-13-14-13-7
Cash Flows TTM          
FCF from Operations TTM-52-59-71-74-72-60-47---
Returns to Shareholders Quarterly          
Dividends0000000000
Share Repurchases-0-0-0-0-0-0-0-0-0-0
Return on Invested Capital (ROIC) Quarterly          
ROIC-42.6%-43.1%-39.2%--66.1%-----
Return on Invested Capital (ROIC) TTM          
ROIC TTM-37.4%-41.4%-51.8%--78.0%-----

Price Behavior

LENZ Betas & Captures as of 9/30/2025

 1M2M3M6M1Y3Y
Beta-0.51-0.79-0.251.431.670.96
Up Beta-2.69-2.54-1.361.361.520.76
Down Beta4.352.481.071.911.962.88
Up Capture145%117%133%167%306%142%
Bmk +ve Days13233574144420
Stock +ve Days14273667134378
Down Capture-413%-475%-275%66%122%52%
Bmk -ve Days8192952107330
Stock -ve Days7152758116353

[1] Upside and downside betas calculated using positive and negative benchmark daily returns respectively

Short Interest

Short Interest: As Of Date10152025
Short Interest: Shares Quantity5,656,845
Short Interest: % Change Since 93020257.3%
Average Daily Volume1,199,623
Days-to-Cover Short Interest4.72
Basic Shares Quantity27,526,099
Short % of Basic Shares20.6%

Earnings Returns History

Expand for More

 Forward Returns
Earnings Date1D Returns5D Returns21D Returns
7/30/2025-2.9%-3.8%18.0%
3/19/20253.1%2.2%-6.7%
11/6/202412.5%30.0%26.0%
8/14/2024-3.8%-4.4%-7.0%
5/8/2024-4.8%-2.1%-3.7%
3/20/2023-4.1%-0.4%20.0%
11/9/20223.0%6.1%0.0%
8/11/20222.3%-3.8%-12.1%
...
SUMMARY STATS   
# Positive534
# Negative687
Median Positive3.1%6.1%19.0%
Median Negative-4.0%-3.8%-10.9%
Max Positive12.5%30.0%26.0%
Max Negative-15.1%-33.6%-50.9%

SEC Filings

Expand for More

Report DateFiling DateFiling
6302025730202510-Q 6/30/2025
3312025507202510-Q 3/31/2025
12312024319202510-K 12/31/2024
93020241106202410-Q 9/30/2024
6302024814202410-Q 6/30/2024
3312024508202410-Q 3/31/2024
123120222132024424B3 12/31/2022

Insider Activity

Expand for More

 

Industry Resources

External Quote Links


Prefer one of these to Trefis? Tell us why.